Effects of saroglitazar in the treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis - 11/08/23
, Shambo Samrat Samajdar b, †, Saibal Das c, d, †Highlights |
• | This meta-analysis evaluated the efficacy and safety of saroglitazar in NAFLD or NASH. |
• | The primary outcome was the change in the serum ALT level. |
• | Saroglitazar could significantly improve liver enzymes and reduce liver stiffness. |
• | It could also improve metabolic parameters in NAFLD or NASH. |
Abstract |
Aim |
This systematic review and meta-analysis was conducted to evaluate the efficacy and safety of 4 mg saroglitazar treatment in patients with non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH).
Methods |
PubMed, Embase, Scopus, Cochrane CENTRAL, medRxiv (pre-print), bioRxiv (pre-print), and ClinicalTrials.gov databases were searched for relevant studies. The primary outcome was the change in the serum alanine transaminase (ALT) level. The secondary outcomes were changes in liver stiffness, liver function test parameters, and metabolic parameters. Pooled mean differences were calculated using random-effects models.
Results |
Of 331 studies that were screened, ten were included. Treatment with adjunct saroglitazar showed a reduction in ALT [mean difference: 26.01 U/L (95% CI: 10.67 to 41.35); p = 0.009; i2: 98%; moderate GRADE evidence] and aspartate transaminase [mean difference: 19.68 U/L (95% CI: 8.93 to 30.43); p<0.001; i2: 97%; moderate GRADE evidence] levels. There was a significant improvement in liver stiffness [mean difference: 2.22 kPa (95% CI: 0.80 to 3.63); p = 0.002; i2: 99%; moderate GRADE evidence]. There were significant improvements in glycated hemoglobin [mean difference: 0.59% (95% CI: 0.32 to 0.86); p<0.001; i2: 78%; moderate GRADE evidence], total cholesterol [mean difference: 19.20 (95% CI: 1.54 to 36.87); p = 0.03; i2: 95%; moderate GRADE evidence], and triglyceride [mean difference: 105.49 mg/dL (95% CI: 11.18 to 199.80); p = 0.03; i2: 100%; moderate GRADE evidence] levels. Saroglitazar treatment was safe.
Conclusion |
Treatment with adjunct 4 mg saroglitazar could significantly improve liver enzymes, reduce liver stiffness, and improve metabolic parameters (serum glucose and lipid profile) in patients with NAFLD or NASH.
Le texte complet de cet article est disponible en PDF.Keywords : Alanine transaminase (ALT), Aspartate transaminase (AST), Fatty liver, Glycated hemoglobin (HbA1C), Lipid profile, Liver stiffness, Non-alcoholic fatty liver disease (NAFLD), Non-alcoholic steatohepatitis (NASH), Saroglitazar
Plan
Vol 47 - N° 7
Article 102174- août 2023 Retour au numéro
Article précédent
- Poor cardiorespiratory fitness may be an indicator of more severe liver inflammation in non-alcoholic fatty liver disease patients
- Luciana Carneiro Pena, Cláudia Alves Couto, Bernardo Henrique Mendes Correa, Luisa Fabiana Queiroz Ferrua, Guilherme Grossi Lopes Cançado, Luciana Costa Faria, Eliane Viana Mancuzo, Teresa Cristina Abreu Ferrari
- Machine learning models predict liver steatosis but not liver fibrosis in a prospective cohort study
- Behrooz Mamandipoor, Sarah Wernly, Georg Semmler, Maria Flamm, Christian Jung, Elmar Aigner, Christian Datz, Bernhard Wernly, Venet Osmani
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?